A new prognostic model could potentially predict and stratify the risk for hepatocellular carcinoma (HCC) among patients with chronic hepatitis B (CHB) who are noncirrhotic and not indicated for ...

Chronic hepatitis B virus (HBV) infection remains a major cause of liver diseases, including cirrhosis and hepatocellular carcinoma. Reliable biomarkers for assessing viral replication, liver damage, ...

- Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of ...

Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model–Based Cost-Effectiveness Analysis This prospective observational study was conducted at ...

A clinical trial led by Kirby Institute at UNSW Sydney has found that point-of-care testing for hepatitis B DNA is as effective as traditional laboratory testing, paving the way for faster diagnosis ...